PL429382A1 - Microparicles based on polylactide, polyglycolide or their copolymers - Google Patents

Microparicles based on polylactide, polyglycolide or their copolymers

Info

Publication number
PL429382A1
PL429382A1 PL429382A PL42938219A PL429382A1 PL 429382 A1 PL429382 A1 PL 429382A1 PL 429382 A PL429382 A PL 429382A PL 42938219 A PL42938219 A PL 42938219A PL 429382 A1 PL429382 A1 PL 429382A1
Authority
PL
Poland
Prior art keywords
inhibitors
active substances
polyglycolide
polylactide
copolymers
Prior art date
Application number
PL429382A
Other languages
Polish (pl)
Other versions
PL241266B1 (en
Inventor
Piotr Waciński
Stanisław Słomkowski
Mariusz Gadzinowski
Original Assignee
Uniwersytet Medyczny W Lublinie
Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie, Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk filed Critical Uniwersytet Medyczny W Lublinie
Priority to PL429382A priority Critical patent/PL241266B1/en
Publication of PL429382A1 publication Critical patent/PL429382A1/en
Publication of PL241266B1 publication Critical patent/PL241266B1/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia są mikrocząstki na bazie polilaktydu, poliglikolidu lub ich kopolimerów, które mają kształt elipsoidalny o różnym stopniu wydłużenia korzystnie, gdy stosunek ich długości do szerokości wynosi około 2:1, przy czym jako substancje aktywne zawierają substancje o charakterze lipofilnym inkorporowane do polimeru w trakcie tworzenia. Mikrocząstki korzystnie jako substancje aktywne zawierają jako substancje aktywne zawierają substancje dobrze rozpuszczalne w dichlorometanie, a słabo rozpuszczalne w wodzie, a w szczególności stawny (inhibitory reduktazy 3-hydroksy-3-metyloglutarylo-koenzymu A (HMG-CoA)) jak: simwastatynę, lowastatynę, prawastatynę, fluwastatynę, pitawastatynę oraz atorwastatynę, cilostazol, 17ß-estradiol, inhibitory białek transportujących estry cholesterolu (cholesterol ester transfer protein (CETP) inhibitors), inhibitory metaloproteinaz.The subject of the application are microparticles based on polylactide, polyglycolide or their copolymers, which have an ellipsoidal shape with a different degree of elongation, preferably when the ratio of their length to width is about 2: 1, with the active substances containing lipophilic substances incorporated into the polymer during creating. As active substances, the microparticles preferably contain as active substances substances that are highly soluble in dichloromethane, and poorly soluble in water, and in particular agitated (3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors) such as: simvastatin, lovastatin, pravastatin, fluvastatin, pitavastatin and atorvastatin, cilostazol, 17β-estradiol, inhibitors of cholesterol ester transfer proteins (CETP) inhibitors, metalloproteinase inhibitors.

PL429382A 2019-03-25 2019-03-25 Use of microparticles based on polylactide, polyglycolide or their copolymers PL241266B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL429382A PL241266B1 (en) 2019-03-25 2019-03-25 Use of microparticles based on polylactide, polyglycolide or their copolymers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL429382A PL241266B1 (en) 2019-03-25 2019-03-25 Use of microparticles based on polylactide, polyglycolide or their copolymers

Publications (2)

Publication Number Publication Date
PL429382A1 true PL429382A1 (en) 2020-10-05
PL241266B1 PL241266B1 (en) 2022-08-29

Family

ID=72669294

Family Applications (1)

Application Number Title Priority Date Filing Date
PL429382A PL241266B1 (en) 2019-03-25 2019-03-25 Use of microparticles based on polylactide, polyglycolide or their copolymers

Country Status (1)

Country Link
PL (1) PL241266B1 (en)

Also Published As

Publication number Publication date
PL241266B1 (en) 2022-08-29

Similar Documents

Publication Publication Date Title
FI3911648T3 (en) 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
GB201121503D0 (en) Medicament delivery technology
DE60031127D1 (en) NSAID AND EGFR KINASE INHIBITORS PHARMACEUTICAL FORMULATION FOR THE TREATMENT OR INHIBITION OF THICK DARMPOLYPES AND COLORECTAL CANCER
ATE353214T1 (en) NITROOXY DERIVATIVES OF FLUVASTATIN, PRAVASTATIN, CERIVASTATIN, ATORVASTATIN AND ROSUVASTATIN AS CHOLESTEROL-LOWERING AGENTS WITH IMPROVED ANTIPHLOGISTIC, ANTITHRBOTIC AND ANTI-PLATE AGGREGATION EFFECTS
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
DE69939481D1 (en) METHOD FOR THE TREATMENT OF DIABETES USING AN AP2 INHIBITOR AND RELATED COMBINATIONS
ATA13602000A (en) STABILIZED PHARMACEUTICAL PREPARATION OF AN HMG-COA REDUCTASE INHIBITOR
IL172875A0 (en) Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
EP1534344A4 (en) VIRUSES AND PSEUDOVIRAL PARTICLES FOR MULTIPLE PRESENTATION OF ANTIGENS AND TARGETS
NO20025784D0 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation which include the same
JP2008522970A5 (en)
FR2838648B1 (en) NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
JP2006512361A5 (en)
IL292829A (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
RU2018133690A (en) TREATMENT OF PATIENTS WITH HOMOSIGOUS FAMILY HYPERCHOLESTERINEMIA GETTING LIPID-REDUCING THERAPY
CY1110043T1 (en) 2-AMINOBENZOUL PRODUCTS
PL429382A1 (en) Microparicles based on polylactide, polyglycolide or their copolymers
JP2013536408A5 (en)
ATE444299T1 (en) NEW BORONATE ESTERS
MX376135B (en) PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG COA REDUCTASE INHIBITORS
EP1275388A4 (en) TNF ALPHA INHIBITORS
ATE418979T2 (en) STABILIZED MEDICINAL PRODUCT AND MEDICINAL PREPARATION
PL3833335T3 (en) Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
PA8622701A1 (en) HYPOOCOLESTEROLEMIATING COMPOSITIONS